Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Verona Pharma

    NASDAQ: VRNA · Real-Time Price · USD
    97.00
    2.68 (2.84%)
    At close: Jun 23, 2025, 3:59 PM
    98.95
    2.01%
    Pre-market: Jun 24, 2025, 08:06 AM EDT
    2.84%
    Bid 97.88
    Market Cap 8.24B
    Revenue (ttm) 118.53M
    Net Income (ttm) -164.02M
    EPS (ttm) -2
    PE Ratio (ttm) -48.5
    Forward PE 88.08
    Analyst Strong Buy
    Ask 99.69
    Volume 1,077,367
    Avg. Volume (20D) 1,416,472
    Open 95.82
    Previous Close 94.32
    Day's Range 94.25 - 97.17
    52-Week Range 14.14 - 97.17
    Beta 0.22

    About VRNA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VRNA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for VRNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Verona Pharma is scheduled to release its earnings on Aug 7, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 week ago
    +3.77%
    Verona Pharma shares are trading higher after Jeff... Unlock content with Pro Subscription
    1 month ago
    +6.38%
    Verona Pharma shares are trading higher after the company reported better-than-expected Q1 revenue results.
    news image

    2 weeks ago · seekingalpha.com

    Verona Pharma: A Blockbuster Franchise In The Making

    Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projec...

    news image

    2 weeks ago · fool.com

    Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today

    If you want to achieve significant gains in the stock market, you'll probably want to plan to hold on and remain invested for many years, or even decades. But in some cases, big payoffs can come much ...

    2 weeks ago · youtube.com

    Mizuho's Jared Holz details potential biotech, pharma acquisitions

    Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.

    news image

    1 month ago · seekingalpha.com

    Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

    VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a pha...

    news image

    1 month ago · seekingalpha.com

    Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

    Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccard...

    news image

    2 months ago · seekingalpha.com

    Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical

    Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is so...

    Add to Watchlist